The fight against cancer received a multi-million dollar boost from GEM Global Yield, an investment vehicle operated by $3.4 billion Luxembourg-based alternative assets firm Global Emerging Markets.
GEM entered into an ongoing commitment to purchase up to $90 million in common shares of NuView Life Sciences, a Park City, Utah-based developer of in vitro cancer diagnostic and theranostics -- that is, products that can diagnose as well as treat disease.
NuView plans to use the funds to complete a 600-patient in vitro double-blind clinical trial to advance its NV-VPAC1 . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.